IMCD ACQUIRES DCS PHARMA AGstrong players join forces
IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and food ingredients, today announces that it successfully completed the acquisition of Swiss pharmaceutical distributor DCS Pharma AG.
With this acquisition IMCD acquired 90% of the shares in DCS Pharma AG. The remaining 10% will follow per 31 December 2021.
IMCD N.V. (“IMCD” or “Company”), a leading distributor of specialty chemicals and food ingredients, today announces that it signed an agreement to acquire in two steps, 100% of the outstanding shares of Swiss based pharmaceutical distributor DCS Pharma AG : 90% of the shares upon fulfilment of transaction-related conditions and the remaining 10% as per 31 December 2021.
John Robinson, IMCD Business Group Director Pharmaceuticals comments, “DCS is a significant acquisition for the development of our Pharmaceutical business, not only in expanding our global footprint, but moreover in exploiting the clear pipeline, formulation and marketing synergies between Active Pharmaceutical Ingredients and Excipients.’’
Beat Berger, CEO DCS Pharma AG adds, “I am absolutely excited about the potential of coupling DCS Pharma’s leading position in Active Pharmaceutical Ingredients with IMCD’s geographic coverage, laboratory network and excellence in Excipients. Our existing and future partners will be able to benefit from a significantly increased network within the pharmaceutical industry.”
DCS PHARMA AG
DCS Pharma AG headquartered in Basel, was founded in 2016 by the two Swiss pharmaceutical distributors Dolder AG and ChemSwiss AG and operates in eight markets such as Spain, Italy, Germany, Mexico, and China. In 2018, the company generated a revenue of CHF 68 million with 64 employees. DCS’ product portfolio covers a range of Active Pharmaceutical Ingredients for the pharmaceutical and nutraceutical industries.
IMCD is a market-leader in the sales, marketing and distribution of speciality chemicals and food ingredients. Its result-driven professionals provide market-focused solutions to suppliers and customers across EMEA, Asia-Pacific and Americas, offering a range of comprehensive product portfolios, including innovative formulations that embrace industry trends. Listed at Euronext, Amsterdam (IMCD), IMCD realised revenues of € 2,379 million in 2018 with more than 2,800 employees in over 47 countries on 6 continents. IMCD's dedicated team of technical and commercial experts work in close partnership to tailor best in class solutions and provide value through expertise for around 43,000 customers and a diverse range of world class suppliers.